Aaron M. Ring, M.D./Ph.D.

Affiliations: 
2016- Yale University School of Medicine, New Haven, CT 
Area:
Immunology, protein engineering, pharmacology, cancer immunotherapy
Website:
https://medicine.yale.edu/immuno/programs/aaron_ring-2.profile
Google:
"Aaron Ring"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

McMahon C, Baier AS, Pascolutti R, et al. (2018) Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nature Structural & Molecular Biology
Barkal AA, Weiskopf K, Kao KS, et al. (2018) Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology. 19: 76-84
Ring NG, Herndler-Brandstetter D, Weiskopf K, et al. (2017) Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proceedings of the National Academy of Sciences of the United States of America
Gordon SR, Maute RL, Dulken BW, et al. (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature
Ho CC, Chhabra A, Starkl P, et al. (2017) Decoupling the Functional Pleiotropy of Stem Cell Factor by Tuning c-Kit Signaling. Cell. 168: 1041-1052.e18
Weiskopf K, Anderson KL, Ito D, et al. (2016) Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20. Cancer Immunology Research
Pascolutti R, Sun X, Kao J, et al. (2016) Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. Structure (London, England : 1993)
Chhabra A, Ring AM, Weiskopf K, et al. (2016) Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Science Translational Medicine. 8: 351ra105
Weiskopf K, Jahchan NS, Schnorr PJ, et al. (2016) CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. The Journal of Clinical Investigation
Mitra S, Ring AM, Amarnath S, et al. (2015) Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity. 42: 826-38
See more...